Literature DB >> 12768335

Visualisation of the normal adrenals at SPET examination with 111In-pentetreotide.

Hans Jacobsson1, Staffan Bremmer, Stig A Larsson.   

Abstract

On single-photon emission tomography (SPET) examinations with indium-111 pentetreotide, we have often observed a small "hot" spot close to the upper portion of the left kidney. While it was initially believed that this represented a tumour in the tail of the pancreas or in the left adrenal, we now understand that it represents normal adrenal uptake. Since the adrenals have not been described as normally visualised, this uptake may interfere with the interpretation of the examination. We have studied how often the normal adrenals are visualised at such examinations. One hundred consecutive clinical (111)In-pentetreotide examinations in adults including SPET of the abdomen and with normal findings were studied. All examinations with a hot spot attributable to the adrenals were, when available, compared with computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen performed on clinical grounds within 3 months before or at any time after the scintigraphy. In 11 patients both adrenals were visualised. In 27 patients only the left and in one only the right adrenal was visualised. CT or MRI examinations were available for comparison in 25 of these 39 patients. Two of these showed a pathological finding in the left adrenal. A conservative interpretation is that the normal adrenal is visualised on one or both sides in at least one-quarter of adults at SPET examination with (111)In-pentetreotide.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12768335     DOI: 10.1007/s00259-003-1210-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  7 in total

Review 1.  Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.

Authors:  W A Breeman; M de Jong; D J Kwekkeboom; R Valkema; W H Bakker; P P Kooij; T J Visser; E P Krenning
Journal:  Eur J Nucl Med       Date:  2001-09

2.  Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients.

Authors:  A A Kasperlik-Zeluska; E Rosłonowska; J Słowinska-Srzednicka; B Migdalska; W Jeske; A Makowska; H Snochowska
Journal:  Clin Endocrinol (Oxf)       Date:  1997-01       Impact factor: 3.478

3.  Adrenal glands imaging with indium-111-DTPA-D-Phe1-octreotide following ACTH therapy.

Authors:  M Lorberboym; P Rubin; R Warner; J Machac
Journal:  J Nucl Med       Date:  1997-09       Impact factor: 10.057

4.  Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas.

Authors:  F Gibril; J C Reynolds; C C Chen; F Yu; S U Goebel; J Serrano; J L Doppman; R T Jensen
Journal:  J Nucl Med       Date:  1999-04       Impact factor: 10.057

5.  Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands.

Authors:  J C Reubi; B Waser; J C Schaer; J A Laissue
Journal:  Eur J Nucl Med       Date:  2001-07

Review 6.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

7.  Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.

Authors:  E P Krenning; W H Bakker; P P Kooij; W A Breeman; H Y Oei; M de Jong; J C Reubi; T J Visser; C Bruns; D J Kwekkeboom
Journal:  J Nucl Med       Date:  1992-05       Impact factor: 10.057

  7 in total
  1 in total

Review 1.  Somatostatin receptor SPECT.

Authors:  Giovanna Pepe; Roy Moncayo; Emilio Bombardieri; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.